Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Withdrawal
[32] RCT	3164 people with New York Heart Association (NYHA) functional class II to IV heart failure	Proportion of people withdrawing from RCT 18% with low-dose lisinopril (2.5 or 5.0 mg/day) 17% with high-dose lisinopril (32.5 or 35.0 mg/day) Absolute numbers not reported	Significance not assessed
Adverse effects
[32] RCT	3164 people with NYHA functional class II to IV heart failure	Proportion of people with dizziness 12% with low-dose lisinopril (2.5 or 5.0 mg/day) 19% with high-dose lisinopril (32.5 or 35.0 mg/day) Absolute numbers not reported	Significance not assessed
[32] RCT	3164 people with NYHA functional class II to IV heart failure	Proportion of people with hypotension 7% with low-dose lisinopril (2.5 or 5.0 mg/day) 11% with high-dose lisinopril (32.5 or 35.0 mg/day) Absolute numbers not reported	Significance not assessed
[32] RCT	3164 people with NYHA functional class II to IV heart failure	Proportion of people with worsening renal function 7% with low-dose lisinopril (2.5 or 5.0 mg/day) 10% with high-dose lisinopril (32.5 or 35.0 mg/day) Absolute numbers not reported	Significance not assessed
[32] RCT	3164 people with NYHA functional class II to IV heart failure	Proportion of people with significant change in serum potassium concentration 7% with low-dose lisinopril (2.5 or 5.0 mg/day) 7% with high-dose lisinopril (32.5 or 35.0 mg/day) Absolute numbers not reported	Significance not assessed
[32] RCT	3164 people with NYHA functional class II to IV heart failure	Proportion of people with cough 13% with low-dose lisinopril (2.5 or 5.0 mg/day) 11% with high-dose lisinopril (32.5 or 35.0 mg/day) Absolute numbers not reported	Significance not assessed